超高度近视准分子激光原位角膜磨镶术后屈光回退的临床观察  

Evaluation of the refractive regression of ultrahigh myopia treated with laser in situ keratomileusis

作　　者：费安裕[1] 林咸平[1] 赵春娟[2] 方燕[1] 叶晓玲[1] 崔刚锋[1] 

机构地区：[1]浙江省台州医院眼科中心,临海317000 [2]浙江省台州学院医学院眼科,台州318000

出　　处：《中国眼耳鼻喉科杂志》2011年第3期146-148,共3页Chinese Journal of Ophthalmology and Otorhinolaryngology

摘　　要：目的了解超高度近视行准分子激光原位角膜磨镶术(LASIK)后的屈光回退情况,并探讨影响其回退的主要因素。方法选择近视度数>-9.00D的近视眼患者行LASIK。根据切削光区直径不同分为2组。Ⅰ组:单区切削组,切削区直径6.5mm或6.0mm,共36眼;Ⅱ组:多区切削组,切削区直径≤6.0mm,分6.0、5.5、5.0、4.5mm等多个区,共36眼。分别记录术前、术后第1、3、6、12个月的视力,屈光度,眼压,角膜厚度等情况,分析术后屈光回退与诸多因素之间的关系。结果术后第12个月最佳矫正视力大于等于术前者,Ⅰ组35眼,Ⅱ组34眼,两组差异无统计学意义(P>0.05)。屈光回退Ⅰ组4眼,Ⅱ组16眼,两组差异有统计学意义(P<0.001)。结论 LASIK治疗超高度近视安全、有效,但要考虑术后屈光回退。手术切削区的大小是影响超高度近视术后屈光回退的重要因素,必要时可部分矫正屈光力,以免出现术后并发症。Objective To evaluate the refractive regression of ultrahigh myopia（ dioptre 〉 - 9.00 D） treated with laser in situ keratomileusis（LASIK） and to investigate the main influential factors. Methods Seventy-two eyes from 36 patients were divided into two groups according to the diameter of corneal operative area： group Ⅰ （36 eyes ） , normal LASIK; group Ⅱ （36 eyes）, muhizone ablation（the diameter of corneal operative area was 6.0, 5.5, 5.0, 4.5 mm respectively）. The visual acuity, Diopter, intraocular pressure and corneal thickness was measured in preoperation, 1 month, 3 months, 6 months and 12 months after operation respectively. The relationships between the refractive regression and the relative factors were analyzed. Results There was no significant difference between group Ⅰ and Ⅱ in post- operative visual acuity（ P 〉 0.05 ）. There was significant difference between group Ⅰ and Ⅱ in the refractive regression （P 〈 0. 001 ）. Conclusions LASIK was a safe and effective method for the treatment of ultrahigh myopia. The operative areaof the corneal cutting was the main influential factor on the refractive regression of ultrahigh myopia treated with LASIK. Local Diopter should be corrected to avoid postoperative complications and refractive regression.

关 键 词：超高度近视 准分子激光原位角膜磨镶术 屈光回退 

分 类 号：R779.63[医药卫生—眼科]